Clinical trial NCT00874562: Rapamycin in Relapsed Acute Lymphoblastic Leukemia
Official title: Rapamycin in Relapsed Acute Lymphoblastic Leukemia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Acute Lymphoblastic Leukemia
Keywords: rapamycin
corticosteroid
ALL
Lead sponsor: Dana-Farber Cancer Institute
Sponsor class: OTHER
Collaborators: name: Brigham and Women's Hospital
name: Boston Children's Hospital
name: National Cancer Institute (NCI)
First posted: 2009-04-02
Enrollment: 6
Sex: ALL
Minimum age (years): 365
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL

Brief summary: This is a research study designed to look at the biological effects of two drugs on leukemia cells. In this study, we are comparing the effects of drugs called corticosteroids when used alone or with another drug called rapamycin. Rapamycin is a drug that prevents the body's immune system from working normally. It has been used for many years after kidney transplants to prevent rejection of the organ. Recent work suggests that rapamycin may also help treat leukemia and other cancers.

Detailed description: * Participants will be randomized into two groups; one group will receive corticosteroid alone, and the other group will receive rapamycin and corticosteroid.
* The length of treatment will be 5 days, during which time we will collect blood samples to measure the biologic effects of these drugs. Because these drugs will be given for a short period of time only, this study is not designed to treat or cure the participants leukemia. After the 5-day period, participants may resume other cancer-directed therapies.

Eligibility criteria: Inclusion Criteria:

* Documented acute lymphoblastic leukemia (L1 or L2 subtypes)
* First or subsequent relapse
* 365 days of age or older
* Greater than 7 days from any chemotherapy or immunotherapy, with the exception of intrathecal chemotherapy
* Absolute peripheral leukemia blast count of 1000 cells/ul or greater
* Patient (or parent/guardian if patient is less than 18 years of age) must sign informed consent

Exclusion Criteria:

* Burkitts leukemia (acute lymphoblastic leukemia L3 subtype)
* Uncontrolled active infection
* Pregnancy or mothers who are nursing
* Patient currently taking rapamycin
* Patients with significant liver dysfunction as outlined in protocol
* Severe concurrent disease, which in the judgment of the investigator, would make the patient inappropriate for entry into the study
* Active psychiatric disease, substance abuse, or mental illness that would interfere with cooperation with the requirements of the trial

Primary outcomes:
measure: Compare changes in gene expression signatures in steroid alone versus steroid plus rapamycin treated patients.
timeFrame: 3 years
measure: Compare biologic measures of "pro-apoptotic state" in steroid alone versus steroid plus rapamycin treated patients
timeFrame: 3 years
Secondary outcomes:
measure: Assess clinical response by percent reduction of peripheral leukemia blasts at day 2 of therapy and at completion of the 5-day investigational window
timeFrame: 3 years
Other outcomes:
Locations:
city: Boston
country: United States
facility: Dana-Farber Cancer Institute
state: Massachusetts
Study officials:
affiliation: Dana-Farber Cancer Institute
name: Lewis Silverman, MD
role: PRINCIPAL_INVESTIGATOR
References: